VivoSim Labs (VIVS) Tax Provisions (2015 - 2026)

VivoSim Labs (VIVS) posted quarterly Tax Provisions of $2000.0 for Q3 2025, little changed quarter-over-quarter from $2000.0 in Q2 2024.

VivoSim Labs (VIVS) Tax Provisions (2015 - 2026) Analysis & Trends

VivoSim Labs' Tax Provisions history runs 10 years deep, the most recent figure standing at $2000.0 for Q3 2025.

In Q3 2025, Tax Provisions changed N/A year-over-year to $2000.0; the TTM figure through Mar 2026 stood at $2000.0 (changed 0.0% YoY), while the FY2026 annual figure was $2000.0, changed 0.0% from the prior year.
Tax Provisions for Q3 2025 stood at $2000.0, roughly flat from $2000.0 in the prior quarter.
The five-year high for Tax Provisions was $2000.0 in Q4 2021, with the low at $2000.0 in Q4 2021.
The 5-year median for Tax Provisions is $2000.0 (2021), against an average of $2000.0.
Peak annual rise in Tax Provisions reached 0.0% in 2023, while the deepest fall reached 0.0% in 2023.
VivoSim Labs' Tax Provisions stood at $2000.0 in 2021, then changed by 0.0% to $2000.0 in 2022, then changed by 0.0% to $2000.0 in 2023, then changed by 0.0% to $2000.0 in 2024, then changed by 0.0% to $2000.0 in 2025.
Business Quant data shows VIVS's Tax Provisions at $2000.0 in Q3 2025, $2000.0 in Q2 2024, and $2000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	59.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	15.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	75.45 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	13.31 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-90.33 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	1.90 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	VivoSim Labs	1.49 Mn	1.49 Mn	-	3,000.00

Download Data